Profile data is unavailable for this security.
About the company
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
- Revenue in USD (TTM)602.20m
- Net income in USD466.88m
- Incorporated2000
- Employees1.78k
- LocationHUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
- Phone+852 21281188
- Fax+852 21281778
- Websitehttps://www.hutch-med.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.93bn | 325.00 | -- | 2.93 | -- | 37.21 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Ultragenyx Pharmaceutical Inc | 672.72m | -575.44m | 1.98bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 2.00bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.07bn | 246.00 | 11.34 | 2.48 | 9.90 | 2.51 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.58bn | 323.00 | -- | 7.70 | -- | 7.05 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| HUTCHMED (China) Ltd (ADR) | 602.20m | 466.88m | 2.60bn | 1.78k | 5.52 | 2.09 | 5.41 | 4.31 | 2.68 | 2.68 | 3.45 | 7.05 | 0.3966 | 7.09 | 3.86 | 332,521.80 | 30.79 | -9.55 | 40.72 | -13.77 | 44.15 | 39.84 | 77.64 | -20.32 | 4.51 | -- | 0.07 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.75bn | 705.00 | 73.08 | 6.84 | 58.84 | 2.70 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.92bn | 674.00 | -- | 2.77 | 43.97 | 4.28 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.99bn | 181.00 | 14.20 | 3.26 | 11.71 | 5.17 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 3.01bn | 979.00 | -- | 6.60 | -- | 7.69 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.16bn | 600.00 | 17.66 | 1.73 | 14.59 | 2.86 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Arcutis Biotherapeutics Inc | 317.93m | -44.32m | 3.17bn | 342.00 | -- | 19.68 | -- | 9.96 | -0.3545 | -0.3545 | 2.49 | 1.31 | 0.7866 | 1.75 | 3.63 | 929,616.90 | -10.97 | -61.20 | -16.53 | -68.48 | 89.96 | -- | -13.94 | -406.29 | 3.28 | -2.61 | 0.407 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
Data as of Feb 13 2026. Currency figures normalised to HUTCHMED (China) Ltd's reporting currency: US Dollar USD
2.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management (Singapore) Ltd.as of 31 Dec 2025 | 1.63m | 0.93% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 Dec 2025 | 863.00k | 0.50% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 650.02k | 0.37% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 321.31k | 0.18% |
| AIA Investment Management Pte Ltd.as of 31 Dec 2025 | 315.44k | 0.18% |
| M&G Investment Management Ltd.as of 31 Dec 2025 | 259.03k | 0.15% |
| Amundi (UK) Ltd.as of 30 Sep 2025 | 164.75k | 0.09% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 134.90k | 0.08% |
| Jane Street Capital LLCas of 31 Dec 2025 | 108.00k | 0.06% |
| Saint Olive Gestion SNCas of 30 Jun 2025 | 100.00k | 0.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
